Blazeck, John http://orcid.org/0000-0002-6110-2938
Karamitros, Christos S. http://orcid.org/0000-0002-1393-3083
Ford, Kyle
Somody, Catrina
Qerqez, Ahlam
Murray, Kyle
Burkholder, Nathaniel T.
Marshall, Nicholas
Sivakumar, Anirudh http://orcid.org/0000-0003-0788-6476
Lu, Wei-Cheng
Tan, Bing
Lamb, Candice
Tanno, Yuri
Siddiqui, Menna Y. http://orcid.org/0000-0001-5183-1777
Ashoura, Norah
Coma, Silvia
Zhang, Xiaoyan M.
McGovern, Karen
Kumada, Yoichi
Zhang, Yan Jessie http://orcid.org/0000-0002-9360-5388
Manfredi, Mark
Johnson, Kenneth A. http://orcid.org/0000-0002-6575-2823
D’Arcy, Sheena http://orcid.org/0000-0001-5055-988X
Stone, Everett
Georgiou, George http://orcid.org/0000-0002-8823-3073
Funding for this research was provided by:
American Cancer Society (28252-PF-15-143-01-CDD, 123506-PF-13-354-01-CDD)
University of Texas System Proteomics network
Cancer Prevention and Research Institute of Texas (DP150061, DP150061)
U.S. Department of Health & Human Services | National Institutes of Health (R01GM104896, R01GM125882, RO1 CA189623, RO1 CA189623)
Ikena Oncology
Article History
Received: 17 September 2021
Accepted: 9 September 2022
First Online: 19 October 2022
Competing interests
: J.B., C.S.K., N.M., W.-C.L., G.G. and E.S. are inventors on intellectual property related to this work, including the active patent US9975959B2 and the pending patents US20190350975A1 and US20210207110A1, which are assigned to the Board of Regents of the University of Texas System. G.G., E.S., X.M.Z., K. McGovern, S.C. and M.M. have equity interest in Ikena Oncology, a company pursuing the commercial development of this technology. J.B., C.S.K., C.L. and E.S. have consulted for Ikena Oncology (previously Kyn Therapeutics). The remaining authors declare no competing interests.